{"id":12681,"date":"2026-04-14T18:21:08","date_gmt":"2026-04-14T18:21:08","guid":{"rendered":"https:\/\/medical-article.com\/?p=12681"},"modified":"2026-04-14T18:21:08","modified_gmt":"2026-04-14T18:21:08","slug":"two-visions-for-value-why-gcea-and-hema-clash-on-drug-pricing","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=12681","title":{"rendered":"Two visions for value \u2013 Why GCEA and HEMA clash on drug pricing"},"content":{"rendered":"<p>That is the title of my <a href=\"https:\/\/becarispublishing.com\/digital-content\/blog-post\/perspectives-healthcare-economist-two-visions-value-why-gcea-and-hema-clash-drug\">latest Perspectives from the Healthcare Economist article<\/a> published in <em>The Evidence Base<\/em> this week.  Here is the teaser: <\/p>\n<p> In this guest column, healthcare economist Jason Shafrin\u00a0(FTI Consulting and Mann School of Pharmacy, University of Southern California)\u00a0explores a widening divide over how health systems define value, and what that means for drug pricing and innovation. He contrasts two competing visions of value in health technology assessment (HTA): HEMA\u2019s cautious, budget\u2011constrained approach centered on quality-adjusted life years (QALYs), and\u00a0<a href=\"https:\/\/becarispublishing.com\/action\/doSearch?ConceptID=501680\">generalized cost\u2011effectiveness analysis<\/a>\u00a0(GCEA), which seeks to incorporate broader societal benefits such as risk, equity, and innovation. <\/p>\n<p>The article is in a Q&amp;A format, and aims to answer the following questions: <\/p>\n<p>Why did HEMA write this report?What is generalized cost\u2011effectiveness analysis?Was the HEMA evaluation comprehensive? What were HEMA\u2019s recommendations?Do HTA bodies have to assume a fixed budget?Would use of GCEA increase pharmaceutical spending? Why did one of the HEMA\u2019s own authors claim their evaluation was biased?Why should anyone outside of health economists care about this debate?<\/p>\n<p>To find the answers, you can read the full article <strong><a href=\"https:\/\/becarispublishing.com\/digital-content\/blog-post\/perspectives-healthcare-economist-two-visions-value-why-gcea-and-hema-clash-drug\">here<\/a><\/strong> (registration required, but access is free!). <\/p>","protected":false},"excerpt":{"rendered":"<p>That is the title of my latest Perspectives from the Healthcare Economist article published in The Evidence Base this week. Here is the teaser: In this guest column, healthcare economist Jason Shafrin\u00a0(FTI Consulting and Mann School of Pharmacy, University of Southern California)\u00a0explores a widening divide over how health systems define value, and what that means&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-12681","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/12681"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12681"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/12681\/revisions"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}